Bendamustine for the treatment of relapsed or refractory

HIGHLIGHTS

• who: Top from the Department of Hematology, University Hospital of Caen, Caen, France have published the paper: Bendamustine for the treatment of relapsed or refractory, in the Journal: (JOURNAL)
• what: The authors aimed to assess the efficacy of bendamustine in real life cohort of patients.
• how: The authors showed also an improved outcome if patients had lower than 3 prior therapies lines or IPI lower than 3 (multivariate analysis).

SUMMARY

[19, 20]. In a recently published series describing the population-based experience of the British Columbia Cancer Agency in . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.